Comerica Securities’s Editas Medicine EDIT Stock Holding History

Comerica Securities’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23	Closed	-$204	–	737
2022 Q4	$204	Buy	+23	New	+$252	﹤0.01%	1483

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Comerica Securities's EDIT Position: Q1 2023 in Review

Comerica Securities sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 23 shares — an estimated $204 sold.

Comerica Securities first reported a position in EDIT in Q4 2022 and held it in 1 quarter. The position peaked at $204 in Q4 2022. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

Comerica Securities reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 23 Editas Medicine shares in Q1 2023, an estimated $204.
Comerica Securities first reported a position in Editas Medicine in Q4 2022 and held it in 1 quarter.
Comerica Securities's Editas Medicine position peaked at $204 in Q4 2022.
234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.